246
Views
47
CrossRef citations to date
0
Altmetric
Reviews

Using hydrogen sulfide to design and develop drugs

, , , &
Pages 163-175 | Received 14 Sep 2015, Accepted 17 Nov 2015, Published online: 19 Dec 2015

References

  • Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
  • Wang R. Two’s company, three’s crowd: Can H2S be the third endogenous gaseous transmitter? FASEB J. 2002;16:1792–1798.
  • Stipanuk MH. Sulfur amino acid metabolism: pathways for production and removal of homocysteine and cysteine. Annu Rev Nutr. 2004;24:539–577.
  • Mikami Y, Shibuya N, Kimura Y, et al. Thioredoxin and dihydrolipoic acid are required for 3-mercaptopyruvate sulfurtransferase to produce hydrogen sulfide. Biochem J. 2011;439:479–485.
  • Ishigami M, Hiraki K, Umemura K, et al. A source of hydrogen sulfide and a mechanism of its release in the brain. Antioxid Redox Signal. 2009;11:205–214.
  • Kamoun P. Endogenous production of hydrogen sulfide in mammals. Amino Acids. 2004;26:243–254.
  • Robert K, Vialard F, Thiery E, et al. Expression of the cystathionine beta synthase (CBS) gene during mouse development and immunolocalization in adult brain. J Histochem Cytochem. 2003;51:363–371.
  • Ishii I, Akahoshi N, Yu XN, et al. Murine cystathionine gamma-lyase: complete cDNA and genomic sequences, promoter activity, tissue distribution and developmental expression. Biochem J. 2004;381:113–123.
  • Zhao W, Zhang J, Lu Y, et al. The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J. 2001;20:6008–6016.
  • Yang G, Wu L, Jiang B, et al. H2S as a physiologic vasorelaxant: Hypertension in mice with deletion of cystathionin gamma-lyase. Science. 2008;322:587–590.
  • Kimura H. Hydrogen sulfide: its production, release and functions. Amino Acids. 2011;41:113–121.
  • Olson KR, Whitfield NL, Bearden SE, et al. Hypoxic pulmonary vasodilation: a paradigm shift with a hydrogen sulfide mechanism. Am J Physiol Regul Integr Comp Physiol. 2010;298:R51–60.
  • Li Q, Lancaster JR Jr. Chemical foundations of hydrogen sulfide biology. Nitric Oxide. 2013;35:21–34.

•• A precious and accurate overview on the chemical bases of H2S biological roles.

  • Whitfield NL, Kreimier EL, Verdial FC, et al. Reappraisal of H2S/sulfide concentration in vertebrate blood and its potential significance in ischemic preconditioning and vascular signaling. Am J Physiol Regul Integr Comp Physiol. 2008;294:R1930–7.
  • Nicholls P, Kim JK. Sulphide as an inhibitor and electron donor for the cytochrome c oxidase system. Can J Biochem. 1982;60:613–623.
  • Kabil O, Banerjee R. Redox biochemistry of hydrogen sulfide. J Biol Chem. 2010;285:21903–21907.
  • Paul BD, Snyder SH. H₂S signalling through protein sulfhydration and beyond. Nat Rev Mol Cell Biol. 2012;13:499–507.

•• A concise interesting review on the principal molecular mechanism, accounting for the biological effects of H2S: the protein sulfhydration.

•• A monumental, exhaustive and accurate work, describing in detail the mechanisms and the biological roles of H2S. An essential paper in the field.

  • Aroca A, Serna A, Gotor C, et al. S-Sulfhydration: A cysteine posttranslational modification in plant systems. Plant Physiology. 2015;168:334–342.
  • Waszczak C, Akter S, Eeckhout D, et al. Sulfenome mining in Arabidopsis thaliana. Proc Natl Acad Sci USA. 2014;111:11545–11550.
  • Bucci M, Cirino G. Hydrogen sulphide in heart and systemic circulation. Inflamm Allergy Drug Targets. 2011;10:103–108.
  • Li L, Hsu A, Moore PK. Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulphide in the cardiovascular system and in inflammation-a tale of three gases. Pharmacol Ther. 2009;123:386–400.
  • Yang G, Wang R. H2S and Blood Vessels: An Overview. Handb Exp Pharmacol. 2015;230:85–110.
  • Schleifenbaum J, Köhn C, Voblova N, et al. Systemic peripheral artery relaxation by KCNQ channel openers and hydrogen sulfide. J Hypertens. 2010;28:1875–1882.
  • Martelli A, Testai L, Breschi MC, et al. Vasorelaxation by hydrogen sulphide involves activation of Kv7 potassium channels. Pharmacological Res. 2013;70:27–34.
  • Bucci M, Papapetropoulos A, Vellecco V, et al. Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. Arterioscler Thromb Vasc Biol. 2010;30:1998–2004.
  • Yan H, Du J, Tang C. The possible role of hydrogen sulfide on the pathogenesis of spontaneous hypertension in rats. Biochem Biophys Res Commun. 2004;313:22–27.
  • Wang R, Szabo C, Ichinose F, et al. The role of H2S bioavailability in endothelial dysfunction. Trends Pharmacol Sci. 2015;36:568–578.
  • Brancaleone V, Roviezzo F, Vellecco V, et al. Biosynthesis of H2S is impaired in non-obese diabetic (NOD) mice. Br J Pharmacol. 2008;155:673–680.
  • Zagli G, Patacchini R, Trevisani M, et al. Hydrogen sulfide inhibits human platelet aggregation. Eur J Pharmacol. 2007;559:65–68.
  • Qiao W, Chaoshu T, Hongfang J, et al. Endogenous hydrogen sulfide is involved in the pathogenesis of atherosclerosis. Biochem Biophys Res Commun. 2010;396:182–186.
  • Wang Y, Zhao X, Jin H, et al. Role of hydrogen sulphide in the development of atherosclerotic lesions in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2009;29:173–179.
  • Altaany Z, Moccia F, Munaron L, et al. Hydrogen sulfide and endothelial dysfunction: relationship with nitric oxide. Curr Med Chem. 2014;21:3646–3661.
  • Zanardo RC, Brancaleone V, Distrutti E, et al. Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J. 2006;20:2118–2120.
  • Chunyu Z, Junbao D, Dingfang B, et al. The regulatory effect of hydrogen sulfide on hypoxic pulmonary hypertension in rats. Biochem Biophys Res Commun. 2003;302:810–816.
  • Geng B, Yang J, Qi Y, et al. H2S generated by heart in rat and its effects on cardiac function. Biochem Biophys Res Commun. 2004;313:362–368.
  • Su YW, Liang C, Jin HF, et al. Hydrogen sulfide regulates cardiac function and structure in adriamycin-induced cardiomyopathy. Circ J. 2009;73:741–749.
  • Chang L, Geng B, Yu F, et al. Hydrogen sulfide inhibits myocardial injury induced by homocysteine in rats. Amino Acids. 2008;34:573–585.
  • Testai L, Rapposelli S, Martelli A, et al. Mitochondrial potassium channels as pharmacological target for cardioprotective drugs. Med Res Rev. 2015;35:520–553.
  • Johansen D, Ytrehus K, Baxter GF. Exogenous hydrogen sulfide (H2S) protects against regional myocardial ischemia-reperfusion injury—Evidence for a role of K ATP channels. Basic Res Cardiol. 2006;101:53–60.
  • Calvert JW, Jha S, Gundewar S, et al. Hydrogen sulfide mediates cardioprotection through nrf2 signaling. Circ Res. 2009;105:365–374.
  • Andreadou I, Iliodromitis EK, Szabo C, et al. Hydrogen sulfide and PKG in ischemia-reperfusion injury: sources, signaling, accelerators and brakes. Basic Res Cardiol. 2015;110:52.
  • Costa AD, Garlid KD, West IC, et al. Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res. 2005;97:329–336.
  • Kubo S, Doe I, Kurokawa Y, et al. Hydrogen sulphide causes relaxation in mouse bronchial smooth muscle. J Pharmacol Sci. 2007;104:392–396.
  • Martelli A, Marino A, Citi V, et al. Isothiocyanates and inhibition of mast cell degranulation: Is hydrogen sulfide the real player? Nitric Oxide. 2015;47(Suppl):S32.
  • Roviezzo F, Bertolino A, Sorrentino R, et al. Hydrogen sulfide inhalation ameliorates allergen induced airway hypereactivity by modulating mast cell activation. Pharmacol Res. 2015 [ cited 2015 Aug 1]. DOI:10.1016/j.phrs.2015.07.032.
  • Fiorucci S, Distrutti E, Cirino G, et al. The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology. 2006;131:259–271.
  • Magierowski M, Magierowska K, Kwiecien S, et al. Gaseous mediators nitric oxide and hydrogen sulfide in the mechanism of gastrointestinal integrity, protection and ulcer healing. Molecules. 2015;20:9099–9123.
  • Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci. 1996;16:1066–1071.

•• The beginning of the “new era” of H2S.

  • Kimura H, Nagai Y, Umemura K, et al. Physiological roles of hydrogen sulfide: Synaptic modulation, neuroprotection, and smooth muscle relaxation. Antioxid Redox Signal. 2005;7:795–803.
  • Paul BD, Snyder SH. Neurodegeneration in Huntington’s disease involves loss of cystathionine γ-lyase. Cell Cycle. 2014;13:2491–2493.
  • Zhang X, Bian JS. Hydrogen sulfide: a neuromodulator and neuroprotectant in the central nervous system. ACS Chem Neurosci. 2014;5:876–883.
  • Lee ZW, Teo XY, Tay EY, et al. Utilizing hydrogen sulfide as a novel anti-cancer agent by targeting cancer glycolysis and pH imbalance. Br J Pharmacol. 2014;171:4322–4336.
  • Wu D, Si W, Wang M, et al. Hydrogen sulfide in cancer: Friend or foe? Nitric Oxide. 2015;50:38–45.
  • Szabo C, Coletta C, Chao C, et al. Tumor-derived hydrogen sulfide, produced by cystathionine-β-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. Proc Natl Acad Sci USA. 2013;110:12474–12479.
  • Hellmich MR, Coletta C, Chao C, et al. The therapeutic potential of cystathionine β-synthetase/Hydrogen sulfide inhibition in cancer. Antioxid Redox Signal. 2015;22:424–448.
  • Hegde A, Bhatia M. Hydrogen sulfide in inflammation: friend or foe? Inflamm Allergy Drug Targets. 2011;10:118–122.
  • Wallace JL, Ianaro A, Flannigan KL, et al. Gaseous mediators in resolution of inflammation. Semin Immunol. 2015;27:227–3.
  • Brancaleone V, Mitidieri E, Flower RJ, et al. Annexin A1 mediates hydrogen sulfide properties in the control of inflammation. J Pharmacol Exp Ther. 2014;351:96–104.
  • Beltowski J. Hydrogen sulfide in pharmacology and medicine–An update. Pharmacol Rep. 2015;67:647–658.
  • Zheng Y, Ji X, Ji K, et al. Hydrogen sulfide prodrugs—a review. Acta Pharm Sin. 2015 [ cited 2015 Aug 21]. DOI:10.1016/j.apsb.2015.06.004.

• An interesting and up-dated overview on the medicinal chemistry of H2S-based drugs

  • Hughes MN, Centelles MN, Moore KP. Making and working with hydrogen sulfide: The chemistry and generation of hydrogen sulfide in vitro and its measurement in vivo: a review. Free Radic Biol Med. 2009;47:1346–1353.
  • Li YF, Xiao CS, Hui RT. Calcium sulfide (CaS), a donor of hydrogen sulfide (H(2)S): A new antihypertensive drug? Med Hypoth. 2009;73:445–447.
  • Caliendo G, Cirino G, Santagada V, et al. Synthesis and biological effects of hydrogen sulfide (H2S): development of H2S-releasing drugs as pharmaceuticals. J Med Chem. 2010;53:6275–6286.
  • Benavides GA, Squadrito GL, Mills RW, et al. Hydrogen sulfide mediates the vasoactivity of garlic. Proc Natl Acad Sci USA. 2007;104:17977–17982.
  • Li L, Whiteman M, Guan YY, et al. Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): New insights into the biology of hydrogen sulfide. Circulation. 2008;117:2351–2360.

• The “birth” of the most successful H2S-donor: GYY4137.

  • Martelli A, Testai L, Citi V, et al. Arylthioamides as H2S donors: l-Cysteine-activated releasing properties and vascular effects in vitro and in vivo. ACS Med Chem Lett. 2013;4:904–908.
  • Whiteman M, Li L, Rose P, et al. The effect of hydrogen sulphide donors on lipopolysaccharide-induced formation of inflammatory mediators in macrophages. Antioxid Redox Signal. 2010;12:1147–1154.
  • Whiteman M, Perry A, Zhou Z, et al. Phosphinodithioate and phosphoramidodithioate hydrogen sulfide donors. Handb Exp Pharmacol. 2015;230:337–363.
  • Zhou Z, Von Wantoch Rekowski M, Coletta C, et al. Thioglycine and L-thiovaline: biologically active H₂S-donors. Bioorg Med Chem. 2012;20:2675–2678.
  • Zhao Y, Wang H, Xian M. Cysteine-activated hydrogen sulfide (H2S) donors. J Am Chem Soc. 2011;133:15–17.
  • Zhao Y, Bhushan S, Yang C, et al. Controllable hydrogen sulfide donors and their activity against myocardial ischemia-reperfusion injury. ACS Chem Biol. 2013;8:1283–1290.
  • Zhao Y, Kang J, Park CM, et al. Thiol-activated gem-dithiols: A new class of controllable hydrogen sulfide donors. Org Lett. 2014;16:4536–4539.
  • Martelli A, Testai L, Breschi MC, et al. Hydrogen sulphide: novel opportunity for drug discovery. Med Res Rev. 2012;32:1093–1130.
  • Kashfi K, Olson KR. Biology and therapeutic potential of hydrogen sulfide and hydrogen sulfide-releasing chimeras. Biochem Pharmacol. 2013;85:689–703.

• A rigorous and exhaustive overview on the biology of H2S and on the pharmacological effects of the most important H2S-releasing drugs, with acute insights and clear indication of the future direction of the research in this field.

  • Wu L, Noyan Ashraf MH, Facci M, et al. Dietary approach to attenuate oxidative stress, hypertension, and inflammation in the cardiovascular system. Proc Natl Acad Sci USA. 2004;101:7094–7099.
  • Pei Y1, Wu B, Cao Q, et al. Hydrogen sulfide mediates the anti-survival effect of sulforaphane on human prostate cancer cells. Toxicol Appl Pharmacol. 2011;257:420–428.
  • Wallace JL, Cirino G, Santagada V, et al. Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs. WO2008/009127 A1. 2008.
  • Martelli A, Testai L, Citi V, et al. Pharmacological characterization of the vascular effects of aryl isothiocyanates: is hydrogen sulfide the real player? Vascul Pharmacol. 2014;60:32–41.
  • Citi V, Martelli A, Testai L, et al. Hydrogen sulfide releasing capacity of natural isothiocyanates: is it a reliable explanation for the multiple biological effects of Brassicaceae? Planta Med. 2014;80:610–613.
  • Kondo K, Bhushan S, King AL, et al. H2S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase. Circulation. 2013;127:1116–1127.
  • Polhemus DJ, Li Z, Pattillo CB, et al. A novel hydrogen sulfide prodrug, SG1002, promotes hydrogen sulfide and nitric oxide bioavailability in heart failure patients. Cardiovasc Ther. 2015;33:216–226.
  • Wallace JL. Hydrogen sulfide-releasing anti-inflammatory drugs. Trends Pharmacol Sci. 2007;28:501–505.
  • Sparatore A, Perrino E, Tazzari V, et al. Pharmacological profile of a novel H(2)S-releasing aspirin. Free Rad Biol Med. 2009;46:586–592.
  • Wallace JL, Caliendo G, Santagada V, et al. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol. 2010;159:1236–1246.
  • Wallace JL, Caliendo G, Santagada V, et al. Gastrointestinal safety and antiinflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology. 2007;132:261–271.
  • Martelli A, Testai L, Marino A, et al. Hydrogen sulphide: biopharmacological roles in the cardiovascular system and pharmaceutical perspectives. Curr Med Chem. 2012;19:3325–3336.
  • Sparatore A, Santus G, Del Soldato P. Cardiovascular Agents. WO2008/122356 A1. 2008.
  • Bucci M, Vellecco V, Cantalupo A, et al. Hydrogen sulfide accounts for the peripheral vascular effects of zofenopril independently of ACE inhibition. Cardiovasc Res. 2014;102:138–147.
  • Szczesny B, Módis K, Yanagi K, et al. AP39, a novel mitochondria-targeted hydrogen sulfide donor, stimulates cellular bioenergetics, exerts cytoprotective effects and protects against the loss of mitochondrial DNA integrity in oxidatively stressed endothelial cells in vitro. Nitric Oxide. 2014;41:120–130.
  • Ikeda K, Marutani E, Hirai S, et al. Mitochondria-targeted hydrogen sulfide donor AP39 improves neurological outcomes after cardiac arrest in mice. Nitric Oxide. 2015;49:90–96.
  • Tomasova L, Pavlovicova M, Malekova L, et al. Effects of AP39, a novel triphenylphosphonium derivatised anethole dithiolethione hydrogen sulfide donor, on rat haemodynamic parameters and chloride and calcium Cav3 and RyR2 channels. Nitric Oxide. 2015;46:131–144.
  • Li L, Bhatia M, Zhu YZ, et al. Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse. FASEB J. 2005;19:1196–1198.
  • Whiteman M, Haigh R, Tarr JM, et al. Detection of hydrogen sulfide in plasma and knee-joint synovial fluid from rheumatoid arthritis patients: relation to clinical and laboratory measures of inflammation. Ann NY Acad Sci. 2010;1203:146–150.
  • D’Emmanuele Di Villa Bianca R, Mitidieri E, Di Minno MN, et al. Hydrogen sulphide pathway contributes to the enhanced human platelet aggregation in hyperhomocysteinemia. Proc Natl Acad Sci USA. 2013;110:15812–15817.
  • Asimakopoulou A, Panopoulos P, Chasapis CT, et al. Selectivity of commonly used pharmacological inhibitors for cystathionine β synthase (CBS) and cystathionine γ lyase (CSE). Br J Pharmacol. 2013;169:922–932.
  • Vermeulen M, Klöpping-Ketelaars IW, Van den Berg R, et al. Bioavailability and kinetics of sulforaphane in humans after consumption of cooked versus raw broccoli. J Agric Food Chem. 2008;56:10505–10509.
  • Lawson LD, Gardner CD. Composition, stability, and bioavailability of garlic products used in a clinical trial. J Agric Food Chem. 2005;53:6254–6261.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.